Reports for APOTEX INC
Company Name
APOTEX INC
Totals |
||
Shortage reports |
3526 |
|
| Actual shortage: | 229 (6%) | |
| Anticipated shortage: | 3 (0%) | |
| Avoided shortage: | 11 (0%) | |
| Resolved: | 3283 (93%) | |
Discontinuation Reports |
366 |
|
| To be discontinued: | 24 (7%) | |
| Discontinued: | 342 (93%) | |
| Reversed: | 0 (0%) | |
Late reports |
143 (4%) |
|
Overdue reports |
32 (13%) |
|
Shortage reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-AMIODARONE TABLETS | 200MG | TABLET | Resolved | 2023-09-15 | 2023-09-28 | 204408 |
| APO-AMIODARONE TABLETS | 200MG | TABLET | Resolved | 2024-05-24 | 2024-06-07 | 228816 |
| APO-AMITRIPTYLINE | 50MG | TABLET | Resolved | 2021-06-04 | 2021-06-28 | 140414 |
| APO-AMITRIPTYLINE | 10MG | TABLET | Resolved | 2021-06-25 | 2021-08-31 | 141518 |
| APO-AMITRIPTYLINE | 25MG | TABLET | Resolved | 2021-08-16 | 2022-05-13 | 144195 |
| APO-AMITRIPTYLINE | 50MG | TABLET | Resolved | 2021-10-08 | 2022-05-13 | 146901 |
| APO-AMITRIPTYLINE | 10MG | TABLET | Resolved | 2021-10-22 | 2022-05-13 | 147809 |
| APO-AMITRIPTYLINE | 75MG | TABLET | Resolved | 2021-10-22 | 2022-06-17 | 147812 |
| APO-AMITRIPTYLINE | 10MG | TABLET | Resolved | 2023-10-20 | 2025-01-11 | 207698 |
| APO-AMITRIPTYLINE | 25MG | TABLET | Resolved | 2024-10-10 | 2025-01-11 | 239828 |
| APO-AMLODIPINE | 5.0MG | TABLET | Resolved | 2017-09-26 | 2017-10-03 | 23533 |
| APO-AMLODIPINE | 10.0MG | TABLET | Resolved | 2017-12-12 | 2018-01-24 | 32511 |
| APO-AMLODIPINE | 5.0MG | TABLET | Resolved | 2018-01-10 | 2018-04-19 | 35536 |
| APO-AMLODIPINE | 10.0MG | TABLET | Resolved | 2018-03-05 | 2018-08-14 | 41847 |
| APO-AMLODIPINE | 5.0MG | TABLET | Resolved | 2018-03-13 | 2018-04-19 | 42669 |
| APO-AMLODIPINE | 5.0MG | TABLET | Resolved | 2018-05-02 | 2018-07-25 | 47963 |
| APO-AMLODIPINE | 5.0MG | TABLET | Resolved | 2018-08-09 | 2018-09-29 | 57766 |
| APO-AMLODIPINE | 10.0MG | TABLET | Resolved | 2018-08-27 | 2018-10-19 | 59287 |
| APO-AMLODIPINE | 5.0MG | TABLET | Resolved | 2019-10-09 | 2019-12-09 | 95821 |
| APO-AMLODIPINE | 5.0MG | TABLET | Resolved | 2019-12-05 | 2019-12-16 | 100203 |
Discontinuation reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-BISACODYL | 5MG | TABLET (DELAYED-RELEASE) | Discontinued | 2018-09-07 | 2018-09-15 | 60288 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2018-09-07 | 2018-10-31 | 60291 |
| APO-BOSENTAN | 62.5MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71339 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71342 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | To be discontinued | 2018-09-07 | 2018-09-07 | 60294 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2018-09-07 | 2018-12-28 | 60301 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2020-11-16 | 2020-11-16 | 128438 |
| APO-BROMAZEPAM | 1.5MG | TABLET | To be discontinued | 2018-09-07 | 2018-09-07 | 60304 |
| APO-BROMAZEPAM | 3MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60307 |
| APO-BROMAZEPAM | 6MG | TABLET | Discontinued | 2018-09-07 | 2018-10-19 | 60310 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60313 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60316 |
| APO-CANDESARTAN | 4MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60319 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60322 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60325 |
| APO-CANDESARTAN | 32MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60328 |
| APO-CANDESARTAN/HCTZ | 25MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-05-03 | 41011 |
| APO-CANDESARTAN/HCTZ | 12.5MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41020 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41047 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60331 |